Skip to main content
Premium Trial:

Request an Annual Quote

Muse Bio Closes $23M Series B Financing Round

NEW YORK (GenomeWeb) – Muse Bio announced today that it has raised $23 million through an oversubscribed Series B financing round.

The round was led by Venrock and included Foresite Capital and Paladin Capital, as well as Series A investors NanoDimension and Spruce/MLS.

According to the company, the Series B funding will allow it to accelerate the commercialization of its ForgeCraft genome-editing technology. The technology is based on a multiplex version of CRISPR/Cas9 gene editing called CREATE — short for CRISPR/Cas9-enabled trackable genome engineering — combined with forward design software, proprietary reagents and algorithms, and an automated instrument.

"We are excited to be funded by this high-quality group of investors with a proven track record of success," Muse Bio CEO Kevin Ness said in a statement. "They recognize the value of Muse Bio's technology, which enables scientists to make multiple, clearly defined genomic modifications at any site within a cell's genome in a high-throughput and cost-effective manner."

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.